Model matters: Differences in orthotopic rat hepatocellular carcinoma physiology determine therapy response to sorafenib

Clinical Cancer Research

Volumn 21, Issue 19, 2015, Pages 4440-4450

  Groß, Claudia ^a   Steiger, Katja ^a   Sayyed, Sufyan ^a   Heid, Irina ^a   Feuchtinger, Annette ^b   Walch, Axel ^b   Heß, Julia ^b   Unger, Kristian ^b   Zitzelsberger, Horst ^b   Settles, Marcus ^a   Schlitter, Anna Melissa ^a   Dworniczak, Juliane ^a   Altomonte, Jennifer ^a   Ebert, Oliver ^a   Schwaiger, Markus ^a   Rummeny, Ernst ^a   Steingötter, Andreas ^c   Esposito, Irene ^a,d   Braren, Rickmer ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

DIETHYLNITROSAMINE; FLUORODEOXYGLUCOSE F 18; SORAFENIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRADING; CANCER GROWTH; CHROMOSOME ABERRATION; COHORT ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; FEASIBILITY STUDY; GENETIC HETEROGENEITY; HISTOPATHOLOGY; LIVER CELL CARCINOMA; LIVER INJURY; LONGITUDINAL STUDY; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; TREATMENT RESPONSE; TUMOR VOLUME; ANALOGS AND DERIVATIVES; ANIMAL; BIOPSY; BLOOD; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION; DISEASE MODEL; EXPERIMENTAL LIVER NEOPLASM; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS; BIOPSY; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM GRADING; NEOVASCULARIZATION, PATHOLOGIC; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; RATS;

EID: 84945556187     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2018     Document Type: Article

References (38)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
2. Hayashi M, Matsui O, Ueda K, Kawamori Y, Gabata T, Kadoya M. Progression to hypervascular hepatocellular carcinoma: correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material. Radiology 2002;225:143-9.
3. Braren R, Curcic J, Remmele S, Altomonte J, Ebert O, Rummeny EJ, et al. Free-breathing quantitative dynamic contrast-enhanced magnetic resonance imaging in a rat liver tumor model using dynamic radial T(1) mapping. Invest Radiol 2011;46:624-31.
4. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60.
5. Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol 2011;8:292-301.
6. Landis CS, Li X, Telang FW, Coderre JA, Micca PL, Rooney WD, et al. Determination of the MRI contrast agent concentration time course in vivo following bolus injection: effect of equilibrium transcytolemmal water exchange. Magn Reson Med 2000;44:563-74.
7. Newell P, Villanueva A, Friedman SL, Koike K, Llovet JM. Experimental models of hepatocellular carcinoma. J Hepatol 2008;48:858-79.
8. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7:3129-40.
9. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-90.
10. Braren R, Altomonte J, Settles M, Neff F, Esposito I, Ebert O, et al. Validation of preclinical multiparametric imaging for prediction of necrosis in hepatocellular carcinoma after embolization. J Hepatol 2011;55:1034-40.
11. Altomonte J, Braren R, Schulz S, Marozin S, Rummeny EJ, Schmid RM, et al. Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats. Hepatology 2008;48:1864-73.
12. Abdullah SS, Pialat JB, Wiart M, Duboeuf F, Mabrut JY, Bancel B, et al. Characterization of hepatocellular carcinoma and colorectal liver metastasis by means of perfusion MRI. J Magn Reson Imaging 2008;28:390-5.
13. Aaltonen LA, Hamilton SRWorld Health Organization, International Agency for Research on Cancer. Pathology and genetics of tumours of the digestive system. Lyon Oxford: IARC Press; Oxford University Press (distributor); 2000. 314 p. p.
14. Thoolen B, Maronpot RR, Harada T, Nyska A, Rousseaux C, Nolte T, et al. Proliferative and nonproliferative lesions of the rat and mouse hepatobiliary system. Toxicol Pathol 2010;38(7 Suppl):5S-81S.
15. Neuvial P, Hupe P, Brito I, Liva S, Manie E, Brennetot C, et al. Spatial normalization of array-CGH data. BMC Bioinformatics 2006;7:264.
16. van de Wiel MA, Kim KI, Vosse SJ, van Wieringen WN, Wilting SM, Ylstra B. CGHcall: calling aberrations for array CGH tumor profiles. Bioinformatics 2007;23:892-4.
17. van de Wiel MA, Wieringen WN. CGHregions: dimension reduction for array CGH data with minimal information loss. Cancer Inform 2007;3: 55-63.
18. Schlaeger C, Longerich T, Schiller C, Bewerunge P, Mehrabi A, Toedt G, et al. Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. Hepatology 2008;47:511-20.
19. + T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell 2014;26:549-64.
20. Heindryckx F, Colle I, Van Vlierberghe H. Experimentalmouse models for hepatocellular carcinoma research. Int J Exp Pathol 2009;90:367-86.
21. Wu L, Tang ZY, Li Y. Experimental models of hepatocellular carcinoma: developments and evolution. J Cancer Res Clin Oncol 2009;135:969-81.
22. Lee JS, Thorgeirsson SS. Comparative and integrative functional genomics of HCC. Oncogene 2006;25:3801-9.
23. Polasek M, Fuchs BC, Uppal R, Schuhle DT, Alford JK, Loving GS, et al. Molecular MR imaging of liver fibrosis: a feasibility study using rat and mouse models. J Hepatol 2012;57:549-55.
24. Cho HR, Choi JW, Kim HC, Song YS, Kim GM, Son KR, et al. Sprague-Dawley rats bearing McA-RH7777 cells for study of hepatoma and transarterial chemoembolization. Anticancer Res 2013;33:223-30.
25. Choi JW, Kim H, Kim HC, Lee Y, Kwon J, Yoo RE, et al. Blood oxygen leveldependent MRI for evaluation of early response of liver tumors to chemoembolization: an animal study. Anticancer Res 2013;33:1887-92.
26. Ehling J, Bartneck M, Wei X, Gremse F, Fech V, Mockel D, et al. CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis. Gut 2014;63:1960-71.
27. Coulon S, Heindryckx F, Geerts A, Van Steenkiste C, Colle I, Van Vlierberghe H. Angiogenesis in chronic liver disease and its complications. Liver Int 2011;31:146-62.
28. Worns MA, Galle PR. HCC therapies-lessons learned. Nat Rev Gastroenterol Hepatol 2014;11:447-52.
29. Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009;69:7385-92.
30. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008;359:1995-2004.
31. Rutman AM, Kuo MD. Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging. Eur J Radiol 2009;70:232-41.
32. Segal E, Sirlin CB, Ooi C, Adler AS, Gollub J, Chen X, et al. Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol 2007;25:675-80.
33. Dong A, Yu H, Wang Y, Dong H, Zuo C. FDG PET/CT and enhanced CT imaging of tumor heterogeneity in hepatocellular carcinoma: imagingpathologic correlation. Clin Nucl Med 2014;39:808-10.
34. Kim KA, Park MS, Ji HJ, Park JY, Han KH, Kim MJ, et al. Diffusion and perfusion MRI prediction of progression-free survival in patients with hepatocellular carcinoma treated with concurrent chemoradiotherapy. J Magn Reson Imaging 2014;39:286-92.
35. Lee JH, Lee JM, Kim SJ, Baek JH, Yun SH, Kim KW, et al. Enhancement patterns of hepatocellular carcinomas on multiphasicmultidetector row CT: comparison with pathological differentiation. Br J Radiol 2012;85: e573-83.
36. Stylianopoulos T, Martin JD, Chauhan VP, Jain SR, Diop-Frimpong B, Bardeesy N, et al. Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci U S A 109:15101-8.
37. Jaworski M, Ittrich C, Hailfinger S, Bonin M, Buchmann A, Schwarz M, et al. Global gene expression in Ha-ras and B-raf mutated mouse liver tumors. Int J Cancer 2007;121:1382-5.
38. Horwitz E, Stein I, Andreozzi M, Nemeth J, Shoham A, Pappo O, et al. Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment. Cancer Discov 2014;4:730-43.